A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

  • STATUS
    Recruiting
  • participants needed
    105
  • sponsor
    Sanofi
Send
Updated on 11 March 2025
See if I qualify

Summary

This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.

Description

The study duration will be up to 27 weeks, with a treatment duration approximately 24 weeks.

Details
Condition Type 2 Diabetes
Age 18years or above
Clinical Study IdentifierNCT06716424
SponsorSanofi
Last Modified on11 March 2025

Eligibility

 Yes No Not Sure

Inclusion Criteria

Participants must be ≥18 years of age, at the time of signing the informed consent
Participants with Type 2 Diabetes diagnosed for at least 1 year at the time of screening on treatment with Metformin +/- OADs or basal insulin/GLP-1RA for a minimum period of 6 months prior to screening
HbA1c between ≥ 7.5% and ≤10.5% inclusive, during screening
Participant with BMI >= 25 kg/m2 (as per Endocrine Society of India, Ref 12)
Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 1 week after the last dose of study intervention (i.e., until Week 27)
Signed informed consent

Exclusion Criteria

Participants are excluded from the study if any of the following criteria
apply
Type 1 Diabetes mellitus or any diabetes other than T2DM
Prior use of any combination of Basal Insulin + GLP-1 RA Fixed Ratio or Free Combination, Premix Insulin, Basal bolus therapy
Basal insulin dose >50 U at screening
Any clinically-significant abnormality identified either in medical history or during screening evaluation (e.g., physical examination, laboratory tests, electrocardiogram, vital signs) or any AEs during screening period, which in judgment of the Investigator would preclude safe completion of the study or constrains efficacy assessment
Known presence of factors that interfere with the HbA1c measurement (e.g., specific hemoglobin variants, hemolytic anemia) compromising the reliability of HbA1c assessment or medical conditions that affect interpretation of HbA1c results (e.g., blood transfusion or severe blood loss in the last 3 months prior to baseline, any condition that shortens erythrocyte survival)
History of severe hypoglycemia requiring emergency room admission or hospitalization within 3 months prior to screening visit
Proliferative retinopathy or maculopathy requiring treatment according to the Investigator
Use of weight loss drugs (including over-the-counter and herbal medications) within 12 Weeks prior to the screening visit
Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 2 weeks or more within 8 weeks prior to screening visit
Likelihood to require treatment prohibited by the protocol during the study
Exposure to any investigational drugs in the last 4 weeks or 5 half-lives, whichever is longer, prior to screening visit or concomitant enrollment in any other clinical study involving an investigational study treatment
Any specific situation during study implementation/course that may raise ethics considerations
History of hypoglycemia unawareness
Patients with known hypersensitivity to lixisenatide, insulin glargine or to any of the inactive ingredients in the formulation
History of drug or alcohol abuse within 6 months prior to screening visit
The above information is not intended to contain all considerations relevant
to a participant's potential participation in a clinical trial
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.